Login / Signup

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.

Peter C TaylorGeorg SchettThomas Wj HuizingaQingmin WangFowzia IbrahimBei ZhouSophia G LivaJafar Sadik B ShaikYuan XiongJocelyn H LeuRohit A PanchakshariMatthew J LozaKeying MaHarman DhattRicardo Rojo CellaChetan S KaryekarCarolyn A CuffSheng GaoKaiyin Fei
Published in: RMD open (2024)
NCT04991753.
Keyphrases
  • rheumatoid arthritis
  • monoclonal antibody
  • disease activity
  • ankylosing spondylitis
  • interstitial lung disease
  • stem cells
  • systemic lupus erythematosus
  • systemic sclerosis
  • replacement therapy